ALEBUND-B (09637.HK): IPO Subscription Period Closes, Margin Subscription Totals HK$40.611 Billion, Listing Scheduled for 29 June
NewTimeSpace News: The IPO subscription period of Alebund Pharmaceuticals (Jiangsu) Limited (09637.HK) closed on 24 June. As of 8 a.m., total margin subscription funds reached approximately HK$40.611 billion, representing an oversubscription multiple of roughly 316 times against the HK$128 million public offering fundraising amount. The Company’s grey market trading is scheduled for 26 June, with formal listing on the Main Board of the Hong Kong Stock Exchange slated for 29 June.
NewTimeSpace News: Alebund Pharmaceuticals (Jiangsu) Limited (09637.HK) wrapped up its IPO subscription period on 24 June 2026. As of 8 a.m., aggregate margin subscription funds stood at about HK$40.611 billion, translating to an oversubscription multiple of approximately 316 times based on the HK$128 million fundraising target for the public tranche.
The IPO subscription window ran from 18 June to 24 June with a fixed offer price of HK$22.6 per share. Each board lot contains 100 shares, with a minimum entry cost of HK$2,282.79 per application. The Company offered 56.75 million H-shares under the global offering, including 5.67 million shares for public subscription, raising around HK$1.181 billion in total gross proceeds.
Alebund Pharmaceuticals is a biopharmaceutical enterprise focusing on therapeutics for kidney diseases. Its core product AP301, a phosphate binder developed to treat hyperphosphatemia, has completed Phase III registration clinical trials in China, and the New Drug Application (NDA) is expected to be submitted in the near term. The grey market trading will commence on 26 June, and the official listing on the HKEX Main Board is set for 29 June.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
